# A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis

> **NCT07749157** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 85 (estimated)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** RO7845860

## Key facts

- **NCT ID:** NCT07749157
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11-23
- **Primary completion:** 2031-02-28
- **Final completion:** 2031-02-28
- **Target enrollment:** 85 (ESTIMATED)
- **Last updated:** 2026-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07749157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07749157, "A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07749157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*